Given selinexor's promising activity with other active drug classes for treating MM, and the preclinical findings that combinations of CD38 engagement and XPO1 inhibition are additive or synergistic in killing MM cells (Turner et al, 2017 unpublished results), the current study was conducted to test whether selinexor's synergy with daratumumab will translate to patients with MM. The gene discussed is CD38; the disease is Miyoshi myopathy.